Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Community Health (CYH), Omada Health, Inc. (OMDA) and Eli Lilly & Co (LLY)

Tipranks - Tipranks - Tue Apr 14, 6:02AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Community Health (CYH), Omada Health, Inc. (OMDA) and Eli Lilly & Co (LLY).

Claim 30% Off TipRanks

Community Health (CYH)

Wells Fargo analyst Stephen Baxter assigned a Sell rating to Community Health today and set a price target of $2.00. The company’s shares closed last Friday at $3.15, close to its 52-week low of $2.53.

According to TipRanks.com, Baxter is a 1-star analyst with an average return of -1.4% and a 42.6% success rate. Baxter covers the Healthcare sector, focusing on stocks such as Concentra Group Holdings Parent, Inc., BrightSpring Health Services, Inc., and Molina Healthcare. ;'>

Currently, the analyst consensus on Community Health is a Hold with an average price target of $3.64.

See today’s best-performing stocks on TipRanks >>

Omada Health, Inc. (OMDA)

In a report released today, Craig Hettenbach from Morgan Stanley maintained a Buy rating on Omada Health, Inc., with a price target of $30.00. The company’s shares closed last Friday at $11.41, close to its 52-week low of $10.28.

According to TipRanks.com, Hettenbach is ranked #2872 out of 12128 analysts.

Omada Health, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $21.89, an 83.2% upside from current levels. In a report issued on April 9, Goldman Sachs also assigned a Buy rating to the stock with a $23.00 price target.

Eli Lilly & Co (LLY)

Wells Fargo analyst Mohit Bansal assigned a Buy rating to Eli Lilly & Co today and set a price target of $1280.00. The company’s shares closed last Friday at $939.47, close to its 52-week high of $972.53.

According to TipRanks.com, Bansal is a 5-star analyst with an average return of 9.2% and a 55.6% success rate. Bansal covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., BioMarin Pharmaceutical, and Vertex Pharmaceuticals. ;'>

Currently, the analyst consensus on Eli Lilly & Co is a Strong Buy with an average price target of $1247.71, implying a 29.5% upside from current levels. In a report issued on April 2, J.P. Morgan also reiterated a Buy rating on the stock with a $1300.00 price target.

Read More on CYH:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).